EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy

被引:1
|
作者
Castano, Adam
Heitner, Stephen B. [1 ]
Masri, Ahmad [1 ]
Huda, Ahsan
Calambur, Veena
Bruno, Marianna
Schumacher, Jennifer
Emir, Birol
Isherwood, Catherine
Shah, Sanjiv j. [2 ,3 ]
机构
[1] Pfizer Inc, New York, NY USA
[2] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Amyloidosis Ctr, Portland, OR USA
[3] Northwestern Univ, Feinberg Sch Med, 633 N St Clair St,Suite 19-015, Chicago, IL 60611 USA
关键词
Wild-type transthyretin amyloidosis; cardiomyopathy; heart failure; machine learning; HEART-FAILURE;
D O I
10.1016/j.cardfail.2023.11.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), an increasingly recognized cause of heart failure (HF), often remains undiagnosed until later stages of the disease. Methods and Results: A previously developed machine learning algorithm was simpli fi ed to create a random forest model based on 11 selected phenotypes predictive of ATTRwt-CM to estimate ATTRwt-CM risk in hypothetical patient scenarios. Using U.S. medical claims datasets (IQVIA), International Classi fi cation of Diseases codes were extracted to identify a training cohort of patients with ATTRwt-CM (cases) or nonamyloid HF (controls). After assessment in a 20% test sample of the training cohort, model performance was validated in cohorts of patients with International Classi fi cation of Diseases codes for ATTRwt-CM or cardiac amyloidosis vs nonamyloid HF derived from medical claims (IQVIA) or electronic health records (Optum). The simpli fi ed model performed well in identifying patients with ATTRwt-CM vs nonamyloid HF in the test sample, with an accuracy of 74%, sensitivity of 77%, speci fi city of 72%, and area under the curve of 0.82; robust performance was also observed in the validation cohorts. Conclusions: This simpli fi ed machine learning model accurately estimated the empirical probability of ATTRwt-CM in administrative datasets, suggesting it may serve as an easily implementable tool for clinical assessment of patient risk for ATTRwt-CM in the clinical setting. Brief lay summary: Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM for short) is a frequently overlooked cause of heart failure. Finding ATTRwt-CM early is important because the disease can worsen rapidly without treatment. Researchers developed a computer program that predicts the risk of ATTRwt-CM in patients with heart failure. In this study, the program was used to check for 11 medical conditions linked to ATTRwt-CM in the medical claims records of patients with heart failure. The program was 74% accurate in identifying ATTRwt-CM in patients with heart failure and was then used to develop an educational online tool for doctors (the wtATTR-CM estimATTR). ( J Cardiac Fail 2024;30:778 - 787 )
引用
收藏
页码:778 / 787
页数:10
相关论文
共 50 条
  • [31] Wild-Type Transthyretin Amyloid Cardiomyopathy: The Gordian-Knot of Novel Therapeutic Regimens
    Zegkos, Thomas
    Gossios, Thomas
    Ntelios, Dimitris
    Parcharidou, Despoina
    Karvounis, Haralampos
    Efthimiadis, Georgios
    CARDIOLOGY IN REVIEW, 2023, 31 (01) : 36 - 41
  • [32] Usefulness of automatic assessment for longitudinal strain to diagnose wild-type transthyretin amyloid cardiomyopathy
    Usuku, Hiroki
    Yamamoto, Eiichiro
    Sueta, Daisuke
    Imamura, Kanako
    Oike, Fumi
    Marume, Kyohei
    Ishii, Masanobu
    Hanatani, Shinsuke
    Arima, Yuichiro
    Takashio, Seiji
    Oda, Seitaro
    Kawano, Hiroaki
    Ueda, Mitsuharu
    Matsui, Hirotaka
    IJC HEART & VASCULATURE, 2023, 47
  • [33] SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?
    Luisa Pinheiro, L.
    Castro, M.
    Tinoco, M.
    Pereira, T.
    Mata, E.
    Azevedo, O.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 496 - 497
  • [34] Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk
    Willis, Connor
    Watanabe, Alexandre H.
    Hughes, Justin
    Nolen, Kimberly
    O'Meara, Jason
    Schepart, Alexander
    Bruno, Marianna
    Biskupiak, Joseph
    Kawamoto, Kensaku
    Shara, Nawar
    Kannampallil, Thomas
    FUTURE CARDIOLOGY, 2022, 18 (05) : 367 - 376
  • [35] Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias
    Isotani, Yoshitaka
    Amiya, Eisuke
    Ishida, Junichi
    Ishizuka, Masato
    Hatano, Masaru
    Nakanishi, Koki
    Daimon, Masao
    Komuro, Issei
    OXFORD MEDICAL CASE REPORTS, 2022, 2022 (02):
  • [36] Exercise hemodynamics and mitochondrial oxidative capacity in disease stages of wild-type transthyretin amyloid cardiomyopathy
    Ladefoged, B. Bertil
    Pedersen, A. D.
    Seefeldt, J. M.
    Nielsen, B. R. R.
    Eiskjaer, H.
    Lichscheidt, E. D.
    Clemmensen, T.
    Gillmore, J. D.
    Poulsen, S. H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 74 - 74
  • [37] LEFT ATRIAL RESERVOIR AND STIFFNESS IN PATIENTS WITH WILD-TYPE TRANSTHYRETIN AMYLOID VS HYPERTROPHIC CARDIOMYOPATHY
    Campisi, Mariapaola
    Trimarchi, Giancarlo
    De Sarro, Rosalba
    Poleggi, Cristina
    Luongo, Alfredo
    Teresi, Lucio
    Lofrumento, Francesca
    Restelli, Davide
    Recupero, Antonino
    Zito, Concetta
    Di Bella, Gianluca
    De Gregorio, Cesare
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [38] Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study
    Tini, Giacomo
    Musumeci, Beatrice
    Milani, Paolo
    Zampieri, Mattia
    Caponetti, Angelo Giuseppe
    Fabris, Francesca
    Foli, Andrea
    Argiro, Alessia
    Mazzoni, Carlotta
    Gagliardi, Christian
    Longhi, Simone
    Saturi, Giulia
    Vergaro, Giuseppe
    Aimo, Alberto
    De Fazio, Ludovica
    Varra, Guerino Giuseppe
    Serenelli, Matteo
    Fabbri, Gioele
    De Michieli, Laura
    Palmiero, Giuseppe
    Ciliberti, Giuseppe
    Carigi, Samuela
    Zanoletti, Margherita
    Mandoli, Giulia Elena
    Lucchi, Giulia Ricci
    Rella, Valeria
    Monti, Enrico
    Gardini, Elisa
    Bartolotti, Michela
    Crotti, Lia
    Merli, Elisa
    Mussinelli, Roberta
    Vianello, Pier Filippo
    Cameli, Matteo
    Marzo, Francesca
    Guerra, Federico
    Limongelli, Giuseppe
    Cipriani, Alberto
    Perlini, Stefano
    Obici, Laura
    Perfetto, Federico
    Barbato, Emanuele
    Porto, Italo
    Sinagra, Gianfranco
    Merlo, Marco
    Emdin, Michele
    Biagini, Elena
    Cappelli, Francesco
    Palladini, Giovanni
    Canepa, Marco
    ESC HEART FAILURE, 2025, 12 (01): : 379 - 388
  • [39] Prognostic factors associated with survival in patients with wild-type transthyretin amyloid cardiomyopathy, treated with tafamidis
    Zemljic, G.
    Frljak, S.
    Poglajen, G.
    Zorz, N.
    Cerar, A.
    Okrajsek, R.
    Bajec, T.
    Vrtovec, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 162 - 162
  • [40] Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy
    Ladefoged, Bertil
    Pedersen, Anders Dahl
    Seefeldt, Jacob
    Nielsen, Bent Roni Ranghoj
    Eiskjaer, Hans
    Lichscheidt, Emil
    Clemmensen, Tor
    Gillmore, Julian David
    Poulsen, Steen Hvitfeldt
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (13):